Diabetes, Type I, Streptozotocin-Induced, Rat
CONTACT CUSTOMER SERVICE
ADD TO FAVORITES
ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
Streptozotocin (STZ) is currently the most used diabetogenic agent in new anti-diabetic drugs in experimental animals. This study aims to evaluate the therapeutic efficacy of STZ induced different glucose response.
ORGANISM
Rat
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Test article is administered orally (PO) to a group of 6 male or female Wistar rats weighing 250 ± 50 g, 48 hours after challenge with streptozotocin (65 mg/kg i.v.). Serum glucose is determined by an automated biochemical analyzer TBA-120FR, obtained from each non-fasted animal, 5 minutes before and 90 minutes after test article administration. Doses may be administered PO, IV, IP and SC. Suggested Testing: n=6/group (study design dependent).
CRITERIA FOR SIGNIFICANCE
p<0.05 compared to vehicle control is considered significant activity
TURNAROUND TIME
STANDARD
20 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Metabolic Diseases
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.
ITEM DOES NOT EXIST
© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences